TNXP Tonix Pharmaceuticals Holding Corp.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1430306 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY318.0%
TTM net income YoY-82.4%
TTM EPS YoY-104.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin89.3%
Operating margin-436.3%
Net margin-420.4%
FCF margin-395.0%
EBITDA margin-431.0%
Returns
ROE-84.1%
ROA-73.1%
ROIC (approx.)-387.9%
Asset turnover0.17x
Leverage & solvency
Liabilities / assets17.7%
Debt / equity0.00x
Current ratio4.57x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.91x
Accruals ratio-6.3%
Payout ratio—
Capex / revenue11.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $13.11M | $10.09M | $7.77M | — | — |
| Cost of revenue | $6.64M | $7.76M | $4.74M | — | — |
| Gross profit | $6.47M | $2.33M | $3.03M | — | — |
| R&D expense | $44.49M | $39.97M | $86.66M | $81.88M | $68.84M |
| SG&A expense | $87.68M | $40.10M | $34.75M | $30.21M | $23.47M |
| Operating income | -$125.70M | -$136.70M | -$118.38M | -$112.09M | -$92.31M |
| Interest expense | $89,000 | $1.23M | — | — | — |
| Pretax income | -$34.03M | -$80.59M | -$18.45M | -$21.74M | -$18.60M |
| Net income | -$124.02M | -$130.04M | -$116.66M | -$110.22M | -$92.29M |
| EBITDA | -$123.78M | -$133.28M | -$114.09M | -$110.84M | -$92.26M |
| EPS (basic) | -14.57 | -176.60 | -14,720.25 | -20.01 | -8.10 |
| EPS (diluted) | -14.57 | -176.60 | -14,720.25 | -20.01 | -8.10 |
| Weighted avg. shares (diluted) | 8.51M | 736,339 | 7,925 | 5.84M | 11.39M |
| Balance sheet | |||||
| Cash & equivalents | $207.64M | $99.68M | $25.85M | $120.47M | $178.90M |
| Receivables | $6.27M | $3.68M | — | — | — |
| Inventory | — | $8.41M | $13.64M | — | — |
| Current assets | $228.88M | $119.00M | $47.77M | $130.78M | $189.05M |
| PP&E, net | $44.46M | $42.25M | $94.03M | $93.81M | $50.56M |
| Goodwill | — | — | $965,000 | — | — |
| Intangibles | $120,000 | $120,000 | $9.74M | $120,000 | $120,000 |
| Total assets | $277.17M | $162.89M | $154.46M | $225.69M | $240.90M |
| Current liabilities | $30.84M | $18.31M | $18.88M | $18.18M | $21.72M |
| Short-term debt | — | $2.82M | $2.35M | — | — |
| Long-term debt | — | $4.67M | $6.56M | — | — |
| Total debt | — | $7.49M | $8.91M | — | — |
| Total liabilities | $32.02M | $23.33M | $48.93M | $18.51M | $22.18M |
| Shareholders' equity | $245.15M | $139.56M | $105.53M | $207.18M | $218.72M |
| Net debt | — | -$92.19M | -$16.94M | — | — |
| Shares outstanding | 12.79M | 4.39M | 20,926 | 12.37M | 15.64M |
| Cash flow statement | |||||
| Operating cash flow | -$99.84M | -$60.92M | -$102.00M | -$98.05M | -$75.56M |
| Capital expenditure | $3.37M | $120,000 | $7.89M | $48.15M | $35.31M |
| Free cash flow | -$103.21M | -$61.05M | -$109.90M | -$146.20M | -$110.86M |
| Investing cash flow | -$4.53M | -$120,000 | -$29.07M | -$48.15M | -$35.31M |
| Financing cash flow | $214.53M | $134.87M | $36.52M | $87.84M | $212.49M |
| Depreciation & amortization | $1.93M | $3.42M | $4.29M | $1.25M | $50,000 |
| Stock-based compensation | $6.02M | $4.78M | $9.28M | $10.91M | $7.90M |
| Share buybacks | $13.76M | — | $13.96M | — | — |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.